BSEM
BioStem Technologies, Inc.
There isn't enough reported data to score BSEM yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
BSEM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Strong |
BSEM's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BSEM PE Valuation
BSEM has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BSEM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect BSEM's losses to grow, with revenue declining.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over BSEM on the outlook, with more favorable earnings and revenue expectations.
BSEM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.35 | -387% |
| Q2 2026 | -$1.68 | -251% |
| Q1 2026 | -$1.18 | -183% |
| Q4 2025 | -$0.49 | -134% |
| Q3 2025 | $0.82 | +34% |
| Q2 2025 | $1.11 | +247% |
| Q1 2025 | $1.43 | +$1.63 |
| Q4 2024 | $1.43 | +$1.94 |
BSEM has swung to a loss: it lost $2.35 per share over the past year, after a profit the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over BSEM on earnings quality, reporting a profit while its opponent remains loss making.
BSEM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.6M | -27% |
| Q2 2026 | $7.9M | -84% |
| Q1 2026 | $6.1M | -92% |
| Q3 2025 | $10.5M | -87% |
| Q2 2025 | $49.3M | -34% |
| Q1 2025 | $72.5M | +73% |
| Q4 2024 | $102.9M | +799% |
| Q3 2024 | $82.6M | +2194% |
BSEM's revenue has slid since its 2024 peak: $8M last quarter, down 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -128% | -142 points |
| Q2 2026 | -106% | -107 points |
| Q1 2026 | -145% | -152 points |
| Q3 2025 | 14% | +2.6 points |
| Q2 2025 | 0.2% | -12 points |
| Q1 2025 | 7.2% | -3.8 points |
| Q4 2024 | 8.2% | +33 points |
| Q3 2024 | 11% | -3.5 points |
BSEM's operating margin was −128% last quarter, down 128 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over BSEM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BSEM on profitability, with a higher operating margin.
BSEM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.8M | -$4M |
| Q1 2026 | -$827.3K | -121% |
| Q4 2025 | $2.4M | -70% |
| Q3 2025 | -$4.8M | -152% |
| Q2 2025 | $5.1M | -18% |
| Q1 2025 | $3.9M | +622% |
| Q4 2024 | $8M | +$9.4M |
| Q3 2024 | $9.3M | +$9.8M |
BSEM's free cash flow was −$12M over the past year, against $26M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over BSEM on cash flow, with more consistent year-over-year improvement.
BSEM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +537K shares |
| 1 year | -23% | -5.4M shares |
| 3 years | +32% | +4.4M shares |
| 5 years | +93% | +8.6M shares |
| Available history | +94% | +8.7M shares |
BSEM has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $1.00 |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BSEM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.2x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.6x | Net Cash |
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -0.2x | Net Cash |
| Q1 2024 | 19.3x | High |
BSEM has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
BSEM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 3.2 | Oversold |
BSEM's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BSEM PE vs Healthcare Sector
| Metric | BSEM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BSEM has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BSEM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.07 | 37% below |
| 20 week MA | $3.08 | 58% below |
| 50 week MA | $4.09 | 68% below |
| 100 week MA | $7.27 | 82% below |
| 200 week MA | $6.91 | 81% below |
BSEM is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over BSEM on trend strength, trading above more of its moving averages.
BSEM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.50 | $1.40 | -44% |
| 2021 | $1.40 | $1.10 | -21% |
| 2022 | $1.10 | $3.48 | +216% |
| 2023 | $3.48 | $5.86 | +68% |
| 2024 | $5.86 | $12.7 | +116% |
| 2025 | $12.7 | $3.87 | -69% |
| 2026 YTD | $3.87 | $1.30 | -66% |
BSEM's yearly returns have swung widely, from +216% in 2022 to −69% in 2025. It's down 66% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over BSEM on returns for 2026, with the stronger performance.